Caspase-8 antibody | knockout validation | MBL M058-3

This is a knockout-validated antibody summary, based on the publication "Combination of IAP antagonist and IFNγ activates novel caspase-10- and RIPK1-dependent cell death pathways", as cited below [1]. Labome curates formal publications to compile a list of antibodies with unambiguous specificity within Validated Antibody Database (VAD).

Antibody information

Mouse monoclonal IgG1

Company: MBL

Antibody: Caspase-8

Catalog number: M058-3

Summary: Mouse monoclonal IgG1 against recombinant human Caspase-8 (180-480 aa, terminal C). Reacts with human. Suitable for western blot and immunoprecipitation.

Validation Method

Western blot

Sample

WT and CRISPR/Cas9-mediated CASP8−/− HT29 cells. Cells were lysed in DISC lysis buffer on ice for 20 min before the addition of SDS sample loading buffer or lysed directly in SDS lysis buffer (126 mM Tris-HCl, pH 8, 20% (v/v) glycerol, 4% (w/v) SDS, 0.02% (w/v) bromophenol blue, 5% (v/v) 2-mercaptoethanol) boiled and sonicated.

Blocking agent

5% milk in PBST.

Primary incubation

Diluted in 2% BSA in PBST.

Figure

Immunoblot of Caspase-8 in the indicated cells types after treatment with IFNγ/SM, QVD and Nec-1 or not treated for 24 h. Arrows indicate full-length and processing products of caspases. Please see Figure 5b in the article [1].

Clone note

The same clone (5D3) is sold as LifeSpan Biosciences LS-C179790; MBL International M058-3.

References
  1. Tanzer M, Khan N, Rickard J, Etemadi N, Lalaoui N, Spall S, et al. Combination of IAP antagonist and IFNγ activates novel caspase-10- and RIPK1-dependent cell death pathways. Cell Death Differ. 2017;24:481-491 pubmed publisher